Table 3.
Primary Organisms Among the Patient Cohort
| Organism | Value |
|---|---|
| Gram-negative* | 223 (35.1) |
| Escherichia coli | 95 (15.0) |
| Klebsiella species | 46 (7.2) |
| Pseudomonas aeruginosa | 26 (4.1) |
| Enterobacter species | 13 (2.0) |
| Haemophilusinfluenzae | 12 (1.9) |
| Acinetobacter species | 7 (1.1) |
| Serratia species | 5 (0.8) |
| Stenotrophomonas maltophilia | 6 (0.9) |
| Other gram-negative organisms | 13 (2.0) |
| Gram-positive* | 168 (26.5) |
| Staphylococcus aureus | 74 (11.7) |
| Streptococcus pneumoniae | 37 (5.8) |
| Streptococcusfaecalis | 12 (1.9) |
| Group A Streptococcus species | 8 (1.3) |
| Other β-hemolytic Streptococcus species | 12 (1.9) |
| Viridans Streptococcus species | 9 (1.4) |
| Streptococcus faecium | 12 (1.9) |
| Other gram-positive organisms | 4 (0.6) |
| Yeast/fungus | 59 (9.3) |
| Candida albicans | 40 (6.3) |
| Candida glabrata | 8 (1.3) |
| Candida tropicalis | 5 (0.8) |
| Other Candida species/yeast | 6 (0.9) |
| Anaerobes | 12 (1.9) |
| Clostridium difficile | 7 (1.1) |
| Bacteroides fragilis | 2 (0.3) |
| Other Clostridium species | 1 (0.2) |
| Other anaerobes | 2 (0.3) |
| Other organisms | 11 (1.7) |
| Total culture-positive | 473 (74.5) |
| Total culture-negative | 162 (25.5) |
| Multidrug-resistant | 31 (4.9) |
| Methicillin-resistant Staphylococcus aureus | 17 (2.7) |
| Carbapenem-resistant gram-negative bacteria | 8 (1.3) |
| Vancomycin-resistant enterococci | 3 (0.5) |
| ESBL-producing Enterobacteriaceae | 3 (0.5) |
Data are expressed as no. (%). All percentages are out of the total number of patients in the cohort (n = 635).
Abbreviation: ESBL, extended-spectrum beta-lactamase.
*
Includes multidrug-resistant organisms.